---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-142000"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:56:51.204718+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IO Biotech reports Q1 net loss of $17.0M; Phase 3 melanoma trial on track for mid-2023 enrollment milestone

## Summary
- Net loss $17.0M for Q1 2023, nearly flat vs $17.2M in Q1 2022.
- Cash and equivalents $128.5M as of March 31, 2023; expected to fund operations through Q3 2024.
- Phase 3 pivotal trial (IOB-013) in advanced melanoma: expects 225 patients randomized by mid-2023, full enrollment by end of 2023.
- Phase 2 basket trial (IOB-022) in lung cancer: 4 partial responses, 4 stable disease among 9 evaluable patients; safety consistent.
- FDA cleared IND for IO102-IO103 in neo-adjuvant/adjuvant solid tumors; Phase 2 trial to start H2 2023.

## SEC filing metadata
- accession: 0001193125-23-142000
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312523142000/0001193125-23-142000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312523142000/d471457d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-142000
- JSON: https://secwatch.observer/filing/0001193125-23-142000.json
- Plain text: https://secwatch.observer/filing/0001193125-23-142000.txt

## Key facts
- Earnings Releases
  IO Biotech, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023 was $17.0 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: Net loss for the three months ended March 31, 2023 was $17.0 million
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2023 was $17.0 million, compared to $17.2 million for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523142000/0001193125-23-142000-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.